Achieve Life director granted 47,250 stock options

Achieve Life Sciences director Reid Alexander Waldman received a new stock option grant, giving him the right to buy 47,250 shares of common stock at an exercise price of $5.24 per share.

Rhea-AI Filing Summary

Achieve Life Sciences director Reid Alexander Waldman received a new stock option grant, giving him the right to buy 47,250 shares of common stock at an exercise price of $5.24 per share. These options vest in substantially equal monthly installments over 36 months starting on May 29, 2026, so the award becomes available gradually as he continues serving the company.

The options expire on May 29, 2036 if not exercised, and this grant brings Waldman’s total reported option holdings from this award to 47,250 derivative securities. The transaction is compensation-related rather than an open-market purchase or sale of existing shares.

Insights

Equity compensation analyst

Routine equity grant to director, no open-market trading signal.

The filing shows Reid Alexander Waldman, a director of Achieve Life Sciences, receiving 47,250 stock options at an exercise price of $5.24 per share. This is a standard compensation grant, not a market transaction involving cash buying or selling of shares.

The options vest monthly over 36 months commencing on May 29, 2026, which encourages continued board service. They expire on May 29, 2036, giving a long window to exercise if value develops. With no open-market trades or large dispositions disclosed, the informational signal for investors is limited.

Insider Trade Summary

Grant/Award: 47,250 shares

Grant/Award 1 txn

Insider Waldman Reid Alexander

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	47,250	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 47,250 contracts (Direct)

Footnotes (1)

1. F1. The option will vest in substantially equal monthly installments over 36 months commencing May 29, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Key Figures

Option grant size: 47,250 options Exercise price: $5.24 per share Underlying shares: 47,250 shares +4 more

7 metrics

Option grant size 47,250 options Stock Option (right to buy) granted to director

Exercise price $5.24 per share Conversion or exercise price of options

Underlying shares 47,250 shares Underlying common stock for the option grant

Vesting period 36 months Substantially equal monthly vesting from May 29, 2026

Vesting start date May 29, 2026 Commencement of monthly vesting schedule

Expiration date May 29, 2036 Option expiration if not exercised

Options held after grant 47,250 options Total derivative securities following transaction

Key Terms

Stock Option (right to buy), derivative security, exercise price, vest in substantially equal monthly installments, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

derivative security financial

"transaction_type: derivative"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

exercise price financial

"conversion_or_exercise_price: 5.2400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in substantially equal monthly installments financial

"The option will vest in substantially equal monthly installments over 36 months"

expiration date financial

"expiration_date: 2036-05-29T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Achieve Life Sciences (ACHV) director Reid Waldman report on this Form 4?

The Form 4 reports that director Reid Alexander Waldman received a grant of stock options for 47,250 shares of Achieve Life Sciences common stock, serving as equity compensation rather than a cash purchase or sale of existing shares in the open market.

How many stock options did the ACHV director receive and at what exercise price?

Reid Alexander Waldman received options covering 47,250 shares of Achieve Life Sciences common stock. The options have an exercise price of $5.24 per share, meaning he can buy shares at that price if and when he exercises the options before expiration.

When do Reid Waldman’s Achieve Life Sciences stock options vest?

The options begin vesting on May 29, 2026, in substantially equal monthly installments over 36 months. This schedule means the award becomes fully vested over three years, conditioned on Waldman continuing to provide service to Achieve Life Sciences on each vesting date.

When do the ACHV director’s newly granted stock options expire?

The stock options granted to director Reid Alexander Waldman expire on May 29, 2036, if not exercised earlier. After that expiration date, any unexercised options will lapse, and the right to buy Achieve Life Sciences common stock at $5.24 per share will end.

Does this ACHV Form 4 show any open-market buying or selling of shares?

No, the Form 4 reflects a grant of stock options classified as a derivative security. It does not report any open-market purchases or sales of Achieve Life Sciences common stock, so it mainly documents equity-based compensation rather than trading activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 04:13 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Waldman Reid Alexander

(Last) (First) (Middle)

22722 29TH DR. SE

SUITE 100

(Street)

BOTHELL WASHINGTON 98021

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ACHIEVE LIFE SCIENCES, INC. [ ACHV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$5.24	05/29/2026		A		47,250		(1)	05/29/2036	Common Stock	47,250	$0	47,250	D

Explanation of Responses:

1. The option will vest in substantially equal monthly installments over 36 months commencing May 29, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	Sandra Thomson as attorney-in-fact for Reid Waldman	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)